文献速递浆细胞疾病

双特异性抗体在伴肾功能损害的复发/难治性多发性骨髓瘤中的作用:系统综述

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.
PubMed 文献 · Am J Hematol · 2026-04-02

该系统综述依据PRISMA指南检索至2026年2月2日,纳入11项研究共1117例患者,评估双特异性抗体在伴肾功能损害的复发/难治性多发性骨髓瘤中的疗效与安全性;结果显示伴与不伴肾功能损害患者的ORR、PFS和OS相当,安全性总体可比,仅血小板减少在肾功能损害患者中显著增加。

要点

  • 双特异性抗体在伴肾功能损害的RRMM患者中ORR、PFS和OS与肾功能正常者相当。
  • CRS、ICANS、感染及血液学毒性在肾功能亚组间总体可比。
  • 仅血小板减少在伴肾功能损害患者中发生率显著升高。

核心结论

  • 双特异性抗体在伴肾功能损害的复发/难治性多发性骨髓瘤患者中显示出显著疗效且安全性可控,结局与肾功能保留患者相似。

研究设计与样本

  • 系统综述按照PRISMA指南开展,检索PubMed、Scopus和ScienceDirect截至2026年2月2日,并筛查近3年ASH、IMS、ASCO、EHA、EMN会议摘要。
  • 共纳入11项合格研究,包括3项关键试验和8项真实世界队列,涵盖1117例患者。

主要发现

  • 伴与不伴肾功能损害患者的ORR、PFS和OS相当。
  • CRS、ICANS、感染及血液学毒性的发生率在肾功能亚组间总体可比。
  • 仅血小板减少的发生率在伴肾功能损害患者中显著升高。

临床怎么用

  • 这些发现支持在临床实践和未来临床试验中,对伴肾功能损害的RRMM这一高危人群使用双特异性抗体。

局限性

  • 大多数临床试验排除了显著肾功能不全的个体,导致双特异性抗体在肾功能损害患者中的安全性和有效性此前表征不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options. Although bispecific antibodies (BsAbs) have been approved in RRMM patients, their safety and efficacy in patients with RI remain insufficiently characterized, as most clinical trials excluded individuals with significant renal dysfunction. This systematic review was conducted in accordance with the PRISMA guidelines. PubMed, Scopus, and ScienceDirect were searched up to February 2, 2026, for clinical trials and retrospective real-world studies evaluating BsAbs in RRMM patients with reported data from patients with RI. Abstracts presented in major international scientific congresses over the preceding 3 years, including ASH, IMS, ASCO, EHA, EMN, were also systematically screened. A total of 11 eligible studies were identified, including 3 pivotal trials and 8 real-world cohorts, encompassing 1117 patients. ORR, PFS and OS were comparable between patients with and without RI. Safety profile, including incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), infections and hematologic toxicities were also comparable across renal subgroups. Only the incidence of thrombocytopenia was significantly increased in patients with RI. Overall, BsAbs demonstrate substantial efficacy and manageable safety in RRMM patients with renal dysfunction. Outcomes were similar to those of patients with preserved renal function. These findings support the use of BsAbs in this high-risk population both in clinical practice and in future clinical trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ntanasis-Stathopoulos I, Manganas S, Filippatos C, et al. The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review. Am J Hematol. 2026. PMID: 41927459. doi:10.1002/ajh.70312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。